CCM
AZN icon

Catapult Capital Management’s AstraZeneca AZN Stock Holding History

Catapult Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,000
Closed -$1.07M – 161
2014
Q3 		$1.07M Hold
15,000
– – 0.11% 148
2014
Q2 		$1.11M Buy
+15,000
New +$1.08M 0.12% 159

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Catapult Capital Management's AZN Position: Q2 2014 in Review

Catapult Capital Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 58,771 shares — an estimated $4.25M sold.

Catapult Capital Management first reported a position in AZN in Q1 2014 and held it in 1 quarter. The position peaked at $3.81M in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

  • Catapult Capital Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
  • Catapult Capital Management sold 58,771 AstraZeneca shares in Q2 2014, an estimated $4.25M.
  • Catapult Capital Management first reported a position in AstraZeneca in Q1 2014 and held it in 1 quarter.
  • Catapult Capital Management's AstraZeneca position peaked at $3.81M in Q1 2014.
  • 419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Catapult Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.